Phase I trial of systemic administration of edmonston strain of measles virus, genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma.
Dispenzieri A et al. Leukemia. 2017 Apr 25. doi: 10.1038/leu.2017.120. [Epub ahead of print].

Moving beyond maximum tolerated dose for targeted oncology drugs: Use of clinical utility index to optimize venetoclax dosage in multiple myeloma patients.
Freise KJ et al. Clin Pharmacol Ther. 2017 Apr 17. doi: 10.1002/cpt.712. [Epub ahead of print].

Marizomib for central nervous system-multiple myeloma.
Badros A et al. Br J Haematol. 2017 Apr;177(2):221-225. doi: 10.1111/bjh.14498.

Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma.
Scott EC et al. Haematologica. 2017 Apr 6. pii: haematol.2016.162321. doi: 10.3324/haematol.2016.162321. [Epub ahead of print].